🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

25 results for “Kura” Clear

  1. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  3. Cytarabine

    Kura Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  4. Dexamethasone

    Kura Oncology

    Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  5. Tipifarnib

    Kura Oncology

    HNSCC

    phase 2 small molecule completed

    1 trial

  6. Tipifarnib

    Kura Oncology

    HRAS Gene Mutation

    phase 2 small molecule completed

    1 trial

  7. Tipifarnib

    Kura Oncology

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial

  8. Tipifarnib

    Kura Oncology

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  9. Tipifarnib

    Kura Oncology

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  10. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  11. Ziftomenib

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial

  12. Ziftomenib, Ziftomenib

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  13. A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

    Kura Oncology

    Relapsed and/or refractory Acute Myeloid Leukemia

    phase 1 other active

    1 trial

  14. Darlifarnib

    Kura Oncology

    Solid Tumors With HRAS Alterations

    phase 1 small molecule active

    1 trial

  15. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura Oncology

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial

  16. KO-947

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  17. Tipifarnib

    Kura Oncology

    NSCLC

    phase 1 small molecule terminated

    1 trial

  18. Tipifarnib

    Kura Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  19. Venetoclax

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  20. Ziftomenib

    Kura Oncology

    Relapsed/Refractory KMT2A-r Acute Leukemia

    phase 1 small molecule active

    1 trial

  21. Ziftomenib

    Kura Oncology

    AML

    phase 1 small molecule active

    1 trial

  22. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  23. Ziftomenib

    Kura Oncology

    KMT2A-rearranged

    phase 1 small molecule active

    1 trial

  24. Ziftomenib

    Kura Oncology

    Refractory Acute Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources